- New era of management of patients with haemophilia - replacement therapy with coagulation factors VIII and IX with an extended half-life (EHL)2019 | Second Faculty of Medicine
- Research Report University Hospital for clinical assessment CSL627_1001Publication without faculty affiliation
- Introduction of the treatment with recombinant FVIII has not increased the inhibitor incidence rate in Czech PUPs with haemophilia A2014 | Second Faculty of Medicine
- Inhibitors incidence rate in Czech previously untreated patients with haemophilia A has not increased since introduction of recombinant factor VIII treatment in 20032015 | Second Faculty of Medicine
- Lonoctocog alpha (Afstyla) - new drug for substitution FVIII in patients with haemophilia A2019 | Publication without faculty affiliation
